Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Heart Care, LLC

Neither a doctor nor a teaching hospital

Research payments

$1,071,529

717 payments

Through program year 2025, Advanced Heart Care, LLC is reported as receiving $1,071,529 in research payments, across 717 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $514,402 405
2024 Research $292,598 166
2023 Research $118,047 101
2022 Research $80,619 14
2021 Research $9,667 8
2020 Research $52,792 21
2019 Research $3,404 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Boehringer Ingelheim International GmbH $442,914 412 payments
  2. Novo Nordisk Inc $224,250 240 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $203,949 35 payments
  4. Boehringer Ingelheim Pharma GmbH & Co.KG $181,276 21 payments
  5. Merck Sharp & Dohme Corporation $17,068 8 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $2,073 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) $467,676 222 payments
  2. BAY94-8862 LCM HFmr/pEF (EF 40%) $127,716 23 payments
  3. Nn6018-7527 $117,000 100 payments
  4. Das-7537 $107,250 140 payments
  5. BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fracti $76,233 12 payments
  6. BI 690517+Empa - Placebo+Empa in patients w. HF (LVEF) $50,615 3 payments
  7. Empagliflozin and heart failure (HFpEF) $49,246 24 payments
  8. EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% $36,158 16 payments
  9. A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA $17,068 8 payments
  10. Obesity Long term safety in patients with CV risk $12,000 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record